IODOALPHIONIC ACID

Possibly Marketed Outside US

Details

Stereochemistry	RACEMIC
Molecular Formula	C15H12I2O3
Molecular Weight	494.0629
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0
Stereo Comments	DL-IODOALPHIONIC ACID

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)C(CC1=CC(I)=C(O)C(I)=C1)C2=CC=CC=C2

InChI

InChIKey=IKYIXZSIKOYSLD-UHFFFAOYSA-N

InChI=1S/C15H12I2O3/c16-12-7-9(8-13(17)14(12)18)6-11(15(19)20)10-4-2-1-3-5-10/h1-5,7-8,11,18H,6H2,(H,19,20)

HIDE SMILES / InChI

Molecular Formula	C15H12I2O3
Molecular Weight	494.0629
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20987895 | https://www.ncbi.nlm.nih.gov/pubmed/20785145 | https://www.ncbi.nlm.nih.gov/pubmed/13385321

Iodoalphionic acid is the contrast medium, which was used for gallbladder examination. It is rarely appeared in the colon and, therefore, rarely masked the gallbladder. The density of the shadow produced by Iodoalphionic acid was greater than that produced by iodophthalein. It was reliable peroral cholecystographic medium, which was less objectionable to take and seldom causes vomiting. Diarrhoea occurred in some cases, but not more often than with tetraiodophenolphthalein. The ingestion of Iodoalphionic acid resulted in low thyroidal radioiodine accumulation for periods ranging from a few weeks to many months.

Originator

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Gallbladder disease 13 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20987895 https://www.ncbi.nlm.nih.gov/pubmed/20989933 https://www.ncbi.nlm.nih.gov/pubmed/20785145	Diagnostic		Approved 8583	Biliselectan Approved Use It was used as a peroral cholecystographic agent

Doses

Dose	Population	Adverse events
4.2 g single, oral Studied dose Dose: 4.2 g Route: oral Route: single Dose: 4.2 g Sources: https://pubmed.ncbi.nlm.nih.gov/20785145/	unhealthy, UNKNOWN Health Status: unhealthy Age Group: UNKNOWN Sex: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/20785145/	Other AEs: Unpleasant taste, Nausea... Other AEs: Unpleasant taste (16 patients) Nausea (10 patients) Vomiting (2 patients) Diarrhea (3 patients) pain on micturition (5 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/20785145/

AEs

AE	Significance	Dose	Population
Nausea	10 patients	4.2 g single, oral Studied dose Dose: 4.2 g Route: oral Route: single Dose: 4.2 g Sources: https://pubmed.ncbi.nlm.nih.gov/20785145/	unhealthy, UNKNOWN Health Status: unhealthy Age Group: UNKNOWN Sex: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/20785145/
Unpleasant taste	16 patients	4.2 g single, oral Studied dose Dose: 4.2 g Route: oral Route: single Dose: 4.2 g Sources: https://pubmed.ncbi.nlm.nih.gov/20785145/	unhealthy, UNKNOWN Health Status: unhealthy Age Group: UNKNOWN Sex: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/20785145/
Vomiting	2 patients	4.2 g single, oral Studied dose Dose: 4.2 g Route: oral Route: single Dose: 4.2 g Sources: https://pubmed.ncbi.nlm.nih.gov/20785145/	unhealthy, UNKNOWN Health Status: unhealthy Age Group: UNKNOWN Sex: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/20785145/
Diarrhea	3 patients	4.2 g single, oral Studied dose Dose: 4.2 g Route: oral Route: single Dose: 4.2 g Sources: https://pubmed.ncbi.nlm.nih.gov/20785145/	unhealthy, UNKNOWN Health Status: unhealthy Age Group: UNKNOWN Sex: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/20785145/
pain on micturition	5 patients	4.2 g single, oral Studied dose Dose: 4.2 g Route: oral Route: single Dose: 4.2 g Sources: https://pubmed.ncbi.nlm.nih.gov/20785145/	unhealthy, UNKNOWN Health Status: unhealthy Age Group: UNKNOWN Sex: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/20785145/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inducer 1087 inhibitor 2252	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP19A1 429 CYP1A2 2153 CYP2C19 2057	P-gp 2052

Drug as perpetrator

Target	Modality	Activity
CYP3A4 2633	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/11350#section=Biological-Test-Results Page: 9.0	inconclusive [IC50 17.3768 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/11350#section=Biological-Test-Results Page: 11.0	inconclusive [IC50 38.9018 uM]
CYP19A1 430	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/11350#section=Biological-Test-Results Page: 51.0	no
CYP2C19 2141	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/11350#section=Biological-Test-Results Page: 104.0	no
CYP3A4 2633	inducer 1966 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/11350#section=Biological-Test-Results Page: 93.0	no
CYP1A2 2333	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/11350#section=Biological-Test-Results Page: 10.0	yes [IC50 24.5454 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/11350#section=Biological-Test-Results Page: 5.0	yes [IC50 9.7717 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/11350#section=Biological-Test-Results Page: 93 \| 95	no

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/11350#section=Biological-Test-Results Page: 103.0

PubMed

Title	Date	PubMed
Non-peptidic small-molecule inhibitors of the single-chain hepatitis C virus NS3 protease/NS4A cofactor complex discovered by structure-based NMR screening.	2004-05-06	15115392
[Competitive interrelations between bilirubin and x-ray contrast agents in binding with human serum albumin].	1986-03-01	3709775
[Effect of tri-iodine-containing x-ray contrast substances on the blood coagulation system in an experiment].	1984-07-01	6479314
[Effect of contrast agents on the iodine-absorbing function of the thyroid gland].	1982-03-01	7075759
Unaltered bromsulphalein retention following cholecystography.	1968-10	5682592
[A new mercurometric determination of pheniodol (Coletrast)].	1967-08	5601615
Influence of iodoalphionic acid priodax, with and without thyrotropin, on thyroidal I 131 uptake in euthyroid patients.	1957-01	13385321
Effects of an organic iodine compound priodax on tests of thyroid function.	1957-01	13385320
Cholegraphy; the new contrast medium biligrafin.	1955-05	14398432
[Duodenal intubation of acranil and iodoalphionic acid in therapy of teniasis].	1954-01-01	13189939
[Comparative study of iodopanoic acid (telepaque) and iodoalphionic acid (pheniodol) in cholecystography; densitometric and plainimetric x-ray study of 100 cases].	1954	13222375
A comparative clinical study of priodax and telepague, including 1,000 examinations.	1953-02	13112403
[Comparative cholecystographic study of iodopanoic acid (telepaque) and iodoalphionic acid].	1953	13096516
[Inefficacy of iodoalphionic acid in radical cure of taeniasis].	1952-11-01	13066283
Pseudo-albuminuria following monophen and priodax.	1952-09	14958023
Comparison of cholecystography with iodoalphionic acid (priodax) and a new gallbladder dye, iodopropanoic acid (telepaque).	1952-08	14948365
Absorption and excretion of pheniodol.	1951-07-21	14848542
Absorption and excretion of pheniodol labelled with radioactive iodine.	1951-04	14838872
Priodax and pseudoalbuminuria.	1950-11	14786413
The compatibility of castor oil and priodax in concurrent examination of the colon and gallbladder.	1949-07	18131934
Some experiences with priodax.	1946-06	20987895
Pheniodol, a new dye for cholecystography.	1946-02	20989933
Pheniodol: A Contrast Medium for Cholecystography.	1943-11-27	20785145

Patents

Sample Use Guides

In Vivo Use Guide

4.2 g. suspended in water or milk

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:23:27 GMT 2025` Edited by `admin` on `Mon Mar 31 18:23:27 GMT 2025`
Record UNII	060B6580LL
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BILIOGNOST

Preferred Name

English

IODOALPHIONIC ACID

Common Name

English

COLETRAST

Brand Name

English

TENAMID

Brand Name

English

.BETA.-(4-HYDROXY-3,5-DIIODOPHENYL)-.ALPHA.-PHENYLPROPIONIC ACID

Systematic Name

English

BILITRAST

Brand Name

English

BILISELKTAN

Brand Name

English

BISELECTAN

Brand Name

English

3-(4-HYDROXY-3,5-DIIODOPHENYL)-2-PHENYLPROPIONIC ACID

Systematic Name

English

DIKOL

Brand Name

English

PHENIODOL

Common Name

English

IODOALPHIONIC ACID [MI]

Common Name

English

NSC-404169

Code

English

TENICID

Brand Name

English

JODOBIL

Brand Name

English

DL-IODOALPHIONIC ACID

Common Name

English

BILISELECTAN

Brand Name

English

IODOBIL

Brand Name

English

NSC-11854

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C28500